ILD is a particularly worrisome systemic feature of SjD that may be associated with poorer quality of life outcomes and increased mortality. Prevalence of SjD-ILD has been quoted to occur in 10-20% of SjD patients; however, identification of SjD may vary widely based on the testing methodologies used.
Recent News
Read ArticleRelapse after CD19 CAR-T was rare in lupus and common in anti-synthetase syndrome and Scl-70 scleroderma. Six of seven relapsing patients were treated with BCMA-directed therapy and responded again.
Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for people living with PMR.
ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania.
Her aim was to highlight emerging therapies, preview trials expected to report results in 2027, and define the knowledge gaps in clinical rheumatology and the solutions needed to advance treatment and care.
As a mid-career pediatric rheumatologist and the sole one at my center in Louisiana, leading a Phase 1 CAR-T trial for lupus has been an extraordinary learning experience. I share my reflections and perspective in the hope that it may be helpful to colleagues venturing into this increasingly familiar territory.

Poster Hall